In contrast to paediatric AML patients, differences in EFS were observed when comparing patients with Q1 and Q4 expression levels of MORC4 (p = 0.02) across patients in intermediate and good risk subgroups, and SAGE1 across patients in poor and good risk subgroups. The gene discussed is SAGE1; the disease is acute myeloid leukemia.